Cys797 is in close proximity to the catalytic site of the EGFR kinase domain where ATP binds (Figure 2Bii, ATP analog bound EGFR) and has been the subject of intensive research as numerous tyrosine kinase inhibitors target this site as a treatment for cancer (Figure 2Biii, inhibitor bound EGFR). Here, EGFR is linked to cancer.